Economic Evaluation of Pharmacological Treatments in Dementia Disorders - A Systematic Literature Review

Sanjib Saha (), Ulf-G. Gerdtham, Håkan Toresson (), Lennart Minthon () and Johan Jarl ()
Additional contact information
Sanjib Saha: Health Economics Unit, Department of Clinical Science, Lund University, Sweden, http://portal.research.lu.se/portal/sv/persons/sanjib-saha(1c64b24e-7940-4f9f-a4c2-e2f08125a3dd).html
Håkan Toresson: Clinical Memory Research Unit, Department of Clinical Science, Lund University, Sweden, http://portal.research.lu.se/portal/sv/persons/haakan-toresson(ae18f674-71f6-4a96-b711-b1dc110da57f).html
Lennart Minthon: Clinical Memory Research Unit, Department of Clinical Science, Lund University, Sweden
Johan Jarl: Health Economics Unit, Department of Clinical Science, Lund University, Sweden, Postal: Department of Economics, School of Economics and Management, Lund University, Box 7082, S-220 07 Lund, Sweden, http://portal.research.lu.se/portal/sv/persons/johan-jarl(6e3c22c0-85aa-4998-88cd-7d00c7939b9e).html

No 2018:37, Working Papers from Lund University, Department of Economics

Abstract: The objective is to systematically review the literature on economic evaluations of pharmacological treatments of dementia disorders. A systematic search of published economic evaluation studies in English was conducted using specified key words in relevant databased and websites. Data extracted included methods and empirical evidence (costs, effects, incremental cost-effectiveness ratio) and we assessed if the conclusions made in terms of cost-effectiveness were supported by the reported evidence. The included studies were also assessed for reporting quality using the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklist. Fourteen studies were included in this review. There was a considerable heterogeneity in methodological approaches, use of simulation models, target populations, study time frames, and perspectives as well as comparators used. Keeping these issues in mind, we find that Cholinesterase Inhibitors (ChEIs), and especially donepezil, are dominating no treatment (i.e. less costly and more effective) for mild to moderate AD patients. For moderate to severe AD patients memantine is cost-effective compared to memantine or ChEIs alone. However, the effect of these drugs on survival is yet not established, which could have a major impact on the cost-effectiveness of these drugs. Conclusion: Pharmaceutical treatments are cost-effective comparing to no treatment for dementia patients. However, more research is required on the long-term effectiveness of these drugs, especially on the effects of drugs on survival.

Keywords: Dementia; pharmaceuticals; economic evaluation; Cholinesterase Inhibitors (search for similar items in EconPapers)
JEL-codes: H43 I10 I18 (search for similar items in EconPapers)
Pages: 35 pages
Date: 2018-11-24
New Economics Papers: this item is included in nep-hea
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://lucris.lub.lu.se/ws/portalfiles/portal/195177558/WP18_37 Full text (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:hhs:lunewp:2018_037

Access Statistics for this paper

More papers in Working Papers from Lund University, Department of Economics School of Economics and Management, Box 7080, S-22007 Lund, Sweden. Contact information at EDIRC.
Bibliographic data for series maintained by Iker Arregui Alegria ().